Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Depreciation & Amortization (CF) (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Depreciation & Amortization (CF) readings, the most recent being $12000.0 for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 81.82% to $12000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $90000.0 through Dec 2025, down 71.79% year-over-year, with the annual reading at $90000.0 for FY2025, 71.79% down from the prior year.
  • Depreciation & Amortization (CF) hit $12000.0 in Q4 2025 for Terns Pharmaceuticals, roughly flat from $12000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $172000.0 in Q1 2021 and bottomed at $11000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $84850.0, with a median of $82500.0 recorded in 2024.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 95.45% in 2021 before it plummeted 87.5% in 2025.
  • Terns Pharmaceuticals' Depreciation & Amortization (CF) stood at $114000.0 in 2021, then dropped by 18.42% to $93000.0 in 2022, then decreased by 22.58% to $72000.0 in 2023, then dropped by 8.33% to $66000.0 in 2024, then crashed by 81.82% to $12000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Depreciation & Amortization (CF) are $12000.0 (Q4 2025), $12000.0 (Q3 2025), and $11000.0 (Q2 2025).